A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
A Single-Center Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve From Time Zero to 24 Hours and Rate of Ureagenesis in Healthy Adult Subjects
Sponsor: Ultragenyx Pharmaceutical Inc
Listed as NCT04269122, this observational or N/A phase trial focuses on Ornithine Transcarbamylase Deficiency and remains completed. Sponsored by Ultragenyx Pharmaceutical Inc, it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2020 — Nov 2020 [monthly]
Completed
Status: Recruiting → Completed
-
Mar 2020 — Apr 2020 [monthly]
Recruiting
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ultragenyx Pharmaceutical Inc
For direct contact, visit the study record on ClinicalTrials.gov .